News >

CDK4/6 Inhibitors Show Unmatched OS Benefit in Metastatic HR+ Breast Cancer

Ellie Leick
Published: Tuesday, Nov 12, 2019

Komal Jhaveri, MD

Komal Jhaveri, MD

The recent readout of overall survival (OS) data with CDK4/6 inhibitors in patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer has been unprecedented, according to Komal Jhaveri, MD, FACP.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication